Share on LinkedInShare on LinkedIn

ARTICLE · 05 OCTOBER 2022

Continuous disclosure for life sciences companies

Piper Alderman
Piper Alderman
Contributor
Piper Alderman

Piper Alderman

Helping shape the future of business in Australia with practical, commercial and cutting-edge legal...

View firm profile
Explore more from Piper Alderman

Continuous disclosure is a key challenge for boards of all ASX-Listed companies & in particular for life sciences companies.

AustraliaCorporate/Commercial Law

Continuous disclosure is a key challenge for boards of all ASX-Listed companies. The obligation of "immediate" disclosure of market-sensitive information requires Boards to make quick decisions, sometimes based on incomplete information.

For life sciences companies, there are added complexities such as:

  • providing balanced and clear explanations of highly technical information;
  • juggling disclosure obligations with embargo requirements for thought leadership journals and conferences; and
  • keeping a reasonable flow of announcements over the long development timeline.

These challenges underpin the 'Code of Best Practice for Reporting by Life Science Companies' (the Code), written by ASX, AusBiotech and other key participants in the life science sector1.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from